Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0487-0111 energy expenditure study after weight loss in adults with obesity
NL-OMON61120Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1 trial of amycretin in obesity (3 arms), sponsored by Novo Nordisk. Started Jul 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
obesity
Beyond the preview
Go deeper on NL-OMON61120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61120.